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Background: Transforming growth factor beta (TGF-β1) is a pleiotropic cytokine, which is deregulated in
atherosclerosis; however the role of age in this process is unknown. We aimed to assess whether TGF-β1 signaling
is affected by age.
Methods: Vascular smooth muscle cells (VSMC) were obtained from patients undergoing abdominal surgery. Levels
of TGF-β1 were measured by ELISA in sera from 169 patients undergoing coronary artery bypass grafting (CABG).
The p27 expression was determined by Western blot from internal mammary arteries (IMA) obtained from CABG
patients (n = 13). In VSMC from these patients undergoing abdominal surgery, secretion of TGF-β1 was determined
by ELISA of cell-conditioned media.
Results: In VSMC from aged patients we observed a lower TGF-β1 secretion, measured as TGF-β1 concentration in
cell conditioned medium (p < 0.001). This effect was correlated to an age-dependent decrease of p27 expression in
IMA from aged CABG patients. In a similar manner, there was an age-dependent decrease of serum TGF-β1 levels in
CABG patients (p = 0.0195).
Conclusions: VSMC from aged patients showed a higher degree of cellular senescence and it was associated to a
lower TGF-β1 secretion and signaling.
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Atherosclerosis is the leading global cause of morbimor-
tality [1]. TGF-β1 is a pleiotropic cytokine which is
deregulated in atherosclerosis [2]. However, the role of
aging in atherosclerotic-related TGF-β1 deregulation re-
mains obscure. TGF-β1 signaling is complex and has
many cross-talks with other signaling cascades [2]. One
major common mediator of TGF-β1 signaling is p27,
which links TGF-β and contact inhibition to cell cycle
arrest [3,4].
The role of TGF-β1 is complex and cell-context dependent.
In atherosclerosis, TGF-β1 is considered as a protective
cytokine, which regulates vascular smooth muscle cell* Correspondence: teje@med.ucm.es
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reproduction in any medium, provided the or(VSMC) proliferation and thus decreases intima-media
thickness [2,5]. It is also able to reduce vascular inflamma-
tion due to its inhibitory activity on plaque monocytes
and T cells [6]. This atheroprotective effect is shared by its
signaling protein p27, whose disruption has been shown
to aggravate atherosclerotic lesions in animal models [7,8].
In human vascular samples, atherosclerotic lesions have
been linked to reduced expression of p27 [9,10]. However,
in advanced atherosclerosis TGF-β1 may behave as a
proatherogenic substance by inducing enhanced fibrosis
and increase of vascular tone, possibly by means of a de-
fective signaling [2].
Many vascular phenomena which take part in athero-
sclerosis mimic what can be found in the process of vas-
cular aging [11]. Of note, the role of human vascular aging
in TGF-β1 is still an unexplored area. Moreover, we stillal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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versus biological vascular age in the clinical arena. There-
fore, we aimed to investigate the effect of age in human
VSMC TGF-β1 secretion. In addition, we assessed p27 ex-
pression in a sample of internal mammary arteries (IMA)
of 13 patients undergoing coronary artery bypass graft-
ing (CABG). Eventually, we determined the pre-surgical




For cell cultures, a group of patients was recruited from
the service of Abdominal Surgery (Hospital Clinico San
Carlos, Madrid, Spain). For the study of TGF-β1 in pa-
tients, two groups were recruited from those undergoing
CABG at the Cardiac Surgery Service (Hospital Clinico
San Carlos, Madrid, Spain). The first one (n = 36) was
composed by patients where a remaining IMA segment
was avaliable. From them, in 13 patients the arterial seg-
ment could yield enought protein to be assessed. The
second group (n = 169) included patients with an avail-
able pre-surgical serum sample. In all cases patient data
included: age, gender, active smoker, body mass index
(BMI), cardiovascular risk factors, creatinine, leukocytes,
monocytes and platelets. Clinical and analytical data
of CABG patients from both groups are shown in the
Tables 1 and 2, respectively. In both patient groups,
exclusion criteria included inflammatory disease, renal




Sex (% men) 4 (100%) 9 (90%)
BMI 26.99 ± 1.883 26.85 ± 0.8519
EF 57.5 ± 3.379 53.60 ± 5.494
Tobacco 0 (0%) 5 (50%)
Alcohol 0 (0%) 1 (10%)
Hypertension 3 (75%) 5 (50%)
Dyslipemia 1 (25%) 5 (50%)
DM 0 (0%) 3 (30%)
IM < 30 days 1 (25%) 5 (50%)
Creatinine 0.9925 ± 0.1291 0.9400 ± 0.0718
Leukocytes 7800 ± 1476 7670 ± 606.3
Monocytes 875 ± 232.3 730 ± 109.6
Platelets 244000 ± 38899 236800 ± 27110
*One-way ANOVA. †Chi-squared test.
BMI: body mass index. EF: Ejection fraction. DM: diabetes mellitus. IM < 30 days: myaccording to the Declaration of Helsinki and approved by
the local ethical committee (Ethical Committee, Hospital
Clinico San Carlos, Madrid, Spain). Written informed
consent was obtained from all patients.
Cell cultures
Mesenteric arteries from patients undergoing abdominal
surgery were used for VSMC culture. The arteries were
extracted during the surgical procedure and immediately
kept in RPMI medium (Life-Technologies, Barcelona,
Spain) at 4°C. Whithin the next 3 h, they were mechanic-
ally disrupted in and the extracellular matrix was digested
using collagenase at 4.5% for 3 h at 37°C. Cells were
maintained in RPMI containing 10% foetal calf serum
(FCS) and 1% antibiotic-antimycotic (Life-Technologies,
Barcelona, Spain). The cells exhibited typical “hill and val-
ley” morphology. Vascular smooth muscle cell phenotype
was assessed as positivity for smooth muscle α-actin by
both Western blot and confocal microscop (data not
shown). Experiments were performed between passages 3
and 5. Primary cell cultures were maintained for 3 weeks
in drug-free cell culture medium before a viable cell line
could be obtained.
Extraction of human arteries
Internal mammary arteries (IMA) were collected by the
surgeons during the surgical procedure (Hospital Clinico
San Carlos, Madrid, Spain). They were immediately kept
in RPMI medium at 4°C within the next few minutes.
They were then kept in carbonic ice at -70°C.rgoing CABG whose IMA were used for the study
65-74 >75 P
14 8
69.43 80.63 P < 0.0001*
13 (92.86%) 6 (75%) 0.5129†
27.14 ± 0.641 27.67 ± 0.960 0.9396*
57.36 ± 4.514 60.38 ± 3.407 0.8181*
2 (14.28%) 0 (0%) 0.0281†
0 (0%) 0 (0%) 0.4446†
9 (64.28%) 6 (75%) 0.6871†
6 (42.86%) 5 (62.5%) 0.6414†
5 (35.71%) 4 (50%) 0.3786†
5 (35.71%) 3 (37.50%) 0.7676†
1.065 ± 0.0787 1.030 ± 1.004 0.7326*
7107 ± 301.2 7375 ± 854.6 0.8710*
600.0 ± 43.22 600.0 ± 73.19 0.2599*
216357 ± 12395 183625 ± 2002 0.2949*
ocardial infarction within 30 days before surgery.
Table 2 Clinical and analytical parameters from patients undergoing CABG whose pre-surgical sera were used for the
study
<55 55-64 65-74 >75 P
Number 23 48 61 31
Age 49.61 59.75 69.08 76.77 P < 0.0001*
Sex (% men) 23 (100%) 42 (87.5%) 52 (85.24%) 17 (56.67%) 0.0002†
BMI 26.70 ± 0.643 27.58 ± 0.504 27.60 ± 0.458 27.13 ± 0.645 0.8639*
EF 58.52 ± 3.311 59.83 ± 2.000 59.95 ± 1.822 59.71 ± 2.049 0.4084*
Tobacco 10 (43.48%) 13 (27.08%) 12 (17.64%) 4 (12.90%) 0.0065†
Alcohol 13 (56.52%) 29 (60.42%) 33 (54.10%) 6 (12.90%) 0.0023†
Hypertension 7 (30.43%) 22 (45.83%) 40 (65.57%) 20 (64.52%) 0.012†
Dyslipemia 12 (52.17%) 30 (62.50%) 27 (44.26%) 16 (51.61%) 0.2871*
DM 5 (23.74%) 18 (37.50%) 20 (32.79%) 17 (54.84%) 0.0958†
IM < 30 days 11 (47.83%) 24 (50%) 35 (57.38%) 16 (51.61%) 0.7676†
Creatinine 1.030 ± 0.027 1.060 ± 0.024 1.130 ± 0.027 1.131 ± 0.045 0.0765*
Leukocytes 7854 ± 343.3 7592 ± 272 7466 ± 250.8 7120 ± 406.5 0.5640*
Monocytes 635.7 ± 41.40 612.6 ± 33.45 600.0 ± 24.63 617.7 ± 33.16 0.9078*
Platelets 227000 ± 12379 241128 ± 10477 224164 ± 7085 234452 ± 14260 0.5895*
TGF-β 42.21 ± 2.715 41.87 ± 2.187 36.44 ± 1.669 33.35 ± 2.092 0.0157*
TGF-β/platelet*1000 0.1937 ± 0.0129 0.1842 ± 0.0121 0.1684 ± 0.008 0.1583 ± 0.013 0.2220*
*One-way ANOVA. †Chi-squared test.
BMI: body mass index. EF: Ejection fraction. DM: diabetes mellitus. IM < 30 days: myocardial infarction within 30 days before surgery.
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In cell culture experiments, VSMC obtained from mes-
enteric arteries were cultured in 24-well plates, serum
free-cell conditioned media were extracted at 48 h and
frozen at -70°C. Protein concentration was calculated
using the bicinchionic acid assay. In patients, blood was
centrifuged at 1500 rpm for 15 min; serum was extracted
and frozen at -70°C. In both cases, total levels of TGF-β1
(active plus acid-activatable) were assessed by ELISA
(R&D Systems, Minneapolis, MN, USA). This kit proved
highly reproducible in a large comparative study of several
ELISA kits for TGF-β [12]. For the TGF-β1 levels from cell
conditioned media, data are expressed as pg/mg protein,
Western blotting
We measured the expression of p27 in IMA from CABG
patients. Tissues from IMA were disrupted with TissueLyser
LT apparatus (Qiagen, Chatsworth, California, CA, USA)
in ice-cold lysis buffer containing 50 mM Tris–HCl
pH 7.5, 1% (w/v) Triton X-100, 150 mM NaCl and 1 mM
DTT, supplemented with phosphatase and protease inhib-
itors (Roche Applied Science, Indianapolis, IN, USA).
Lysates were centrifuged at 14000 rpm for 20 min (4°C)
and protein concentration in the supernatants was deter-
mined using the Bradford assay (BioRad Laboratories.
Richmond, CA, USA). Proteins (25 μg) were separated
onto 12% SDS-polyacrylamide gels and Western blot ana-
lysis was carried out using anti-p27 (1/1000, 610242 BDTransduction Laboratories San Diego, CA, USA) and
anti-ERK2 (1/1000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) antibodies. A similar procedure was performed
for Smad2 and Smad3, as well as their phosphorylated
forms (Sigma, Madrid, Spain). Relative protein level was
determined by densitometry using the ImageQuant soft-
ware (Amersham, Uppsala, Sweden).
Statistical analysis
The results are expressed as the mean±SEM (standard
error mean). A statistical analysis of the data was carried
out by a Student’s t test or by a one-way ANOVA when
necessary. Correlations were compared using Pearson’s
correlation test, whereas categorical variables were com-
pared using Chi-squared test. Differences with a p value
of less than 0.05 were considered statistically significant.
Results
Age-dependent defective TGF-β1 secretion in human
VSMC
We aimed to assess whether TGF-β1 secretion was in-
fluenced by age. As shown in Figure 1A, human VSMC
exhibited a progressive age-dependent reduction in the
secretion of TGF-β1, as revealed by analysis of cell
conditioned media. Of note, this decrease was statisti-
cally significant between < 50 and 50–65 years old, and
reached the strongest effect in VSMC from patients aged
> 65 years old.
Figure 1 Age-dependent TGF-β1 concentration. Panel A: Cells
were cultured in plates and conditioned media were collected.
Panel B: Concentration of TGF-β1 was assessed in the pre-surgical
serum of CABG patients according to Methods. *p < 0.05, ***p < 0.001.
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We next tried to assess whether CABG patients, with a
strong burden of angiographically demonstrated ath-
erosclerotic vascular disease, had lower levels of serum
TGF-β1 signaling related to aging. Therefore, we exam-
ined two different groups of patients who underwent
CABG. The first group was composed by 36 patients
where remaining IMA was available for analysis. As
shown in Table 1, in this group only an inverse asso-
ciation with smoking was associated with age. However,
in the second group, composed by CABG patients whose
pre-surgical sera were available (n = 169), old age was as-
sociated to higher percentage of women and hypertension
rate, whereas it was inversely related to smoking, drinking
alcohol and serum levels of TGF-β1 (Table 2). As shown
in Figure 1B, the concentration of TGF-β1 in the pre-
surgical sera of CABG patients was decreased in the oldest
age group in a significant manner. However, TGF-β1 levels
did not vary according to other clinical parameters, suchas pharmacological treatments in the multivariate analysis
(data not shown).
Age-dependent reduction in p27 expression in IMA from
patients
Having demonstrated that TGB-β1 is reduced with aging,
we examined in IMA from CABG patients the expression
of p27, which is a direct marker of TGF-β1 signaling [4].
Western blot analysis revealed a statistically significant
decrease of p27 expression during aging (Figure 2A,
B and C). This reinforces the idea that advanced age
is associated to decreased TGF-β1 signaling in the human
vascular wall when measured as p27 expression, similar to
what found in atherosclerotic lesions [8]. However, when
phosphorylation of Smad2 and Smad3 were assessed,
no significant age-related differences were noted among
different age groups (Figure 3).
Correlations among serum TGF-β1, age and platelets in
CABG patients
Since it is widely accepted that a major amount of serum
TGF-β1 comes from platelets [2] and an age-dependent
platelet decrease has been found in healthy populations
[13], we tried to assess whether age-dependent serum
levels of TGF-β1 were affected by platelet number. First,
a correlation graph was built for TGF-β1 and age. Yet
again, this inverse correlation was statistically significant
(Figure 4A). Moreover, we found a strong positive cor-
relation between serum TGF-β1 and platelets (Figure 4B).
However, the comparison between age and platelets could
not yield a significant association (Figure 4C). Thus, the
age-dependent decrease in serum TGF-β1 in CABG pa-
tients is not a direct consequence of age-related platelet
decrease. This finding is reinforced by the fact that serum
TGF-β1 per platelet remained unchanged among age
groups (Table 2).
Discussion
The present study shows that advanced age implies a de-
crease of TGF-β1 secretion by human VSMC. This age-
dependent TGF-β1 defect is further reproduced in CABG
patients, where an age-dependent defective p27 expression
is found at the vascular level, and pre-surgical serum con-
centrations of TGF-β1 are decreased in aged groups.
Despite that many vascular phenomena found in ath-
erosclerosis are similar to what found in vascular aging
[11], and the fact that the majority of atherosclerotic
patients belong to the elderly [1], the mechanisms under-
lying age-dependent atherosclerotic disease remain poorly
understood. In atherosclerosis, TGF-β1 seems to lose its
atheroprotective effects [2,5]. TGF-β1 exerts its wide var-
iety of biological actions by means of very complex signal-
ing pathways, some of which converge in the expression
of the cell cycle regulatory protein p27 [3,4]. In particular,
Figure 2 Age-dependent decreased p27 in IMA from CABG patients. Panel A: Representative Western blot of p27 expression versus ERK in
IMA from CABG patients. Panel B: p27 expression and age show a significant inverse correlation. Panel C: age-dependent p27 decrease remains
statistically significant when compared among several age groups. *p < 0.05.
Figure 3 Effect of age on Smad2 and Smad3 phosphorylation. Top dot blots show the expression of Smad2 and Smad3 as well as their
phosphorylated forms. Bottom bars show quantifications among different age groups. No significant differences were found.
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Figure 4 Correlations among TGF-β1, age and platelets.
Panel A: Correlation between pre-surgical serum levels of TGF-β1
and age. Panel B: Correlation between pre-surgical serum levels
of TGF-β1 and the number of platelets of the CABG cohort.
Panel C: Correlation between the number of platelets and age.
Pearson’s correlation tests were run according to Methods.
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otic vascular disease in murine models [7,8]. This concept
is reinforced by the fact that human atherosclerosis has
been linked to decreased serum levels of TGF-β [14,15].
At the same time, in animal models atherosclerosis can be
experimentally accelerated when TGF-β1 is inhibited [6].
However, in advanced atherosclerosis, TGF-β1 may be-
have as a proatherogenic stimulus by increasing extracel-
lular matrix formation and fibrosis [16] and subsequenthypertensive organ damage [17] after a progressive loss of
a proper signaling [18], what has been termed the double-
edged sword hypothesis [2]. Thus, decreased TGF-β1 sig-
naling and loss of p27 expression [10] might be considered
as a hallmark of atherosclerosis.
However, no data are available about the effect of age
on TGF-β1 signaling pathway in humans. Our data
clearly show that advanced age is strongly related to a
lower TGF-β1 secretion in human VSMC conditioned
medium (Figure 1A). This is in accordance to our find-
ing of decreased serum levels of TGF-β1 in the oldest
CABG patients (Figure 1B). Moreover, we noted a de-
creased p27 expression in human IMA from CABG pa-
tients (Figure 2A, B and C), although Smad2 and Smad3
phosphorylation was not affected in a significant manner
(Figure 3). Eventually, this association was reinforced
when a correlation was made between serum TGF-β1 and
age in the entire cohort (Figure 4A). This age-dependent
decrease of serum TGF-β1 in our group of CABG patients
is in accordance with results in a Japanese population
study [19], although the role of age in atherosclerosis-
related TGF-β1 deregulation has not been evaluated to
date. Given that the majority of serum TGF-β1 is secreted
by platelets [2] and an age-related platelet decrease have
been noted [13] one could argue that platelets mediate
age-dependent TGF-β1 decrease in our sample. Of note,
cell secretion of this cytokine is a process strictly reg-
ulated and seems to be regulated in an independent man-
ner of its mRNA transcription [2]. However, we found a
strong correlation between serum TGF-β1 and platelets
(Figure 4B), similar to described elsewhere [20], whereas a
significant association between age and platelets was not
noted in our cohort (Figure 4C), possibly related to the
factor that all CABG patients are severely affected by ath-
erosclerosis. This lack of association can be related to a
direct decrease of TGF-β1 from human VSMC in our cell
culture model (Figure 2A) and is reinforced by the fact
that all age groups had similar serum TGF-β1 per platelet
(Table 2). Beyond the major role of platelets, a minor, al-
beit significant, role for VSMC in serum TGF-β1 is coher-
ent to the current scientific evidence [21].
Outcome of CABG is highly variable among patients.
Several risk scores have been established, the euroSCORE
II (which includesx age) being one of the most im-
portant ones [22]. However, many other unknown risk
factors influence CABG outcome [23]. Among them, the
TGF-β1 pathway is implicated in atherosclerosis and car-
diovascular drug response [24]. Adding a measurement of
TGF-β1 function may complement current clinical risk
scores and thus help to discriminate the best clinical
option for every single patient, what can be regarded as a
major clinical need [25]. In addition, correlation of the
TGF-β1 pathway and the amount of cardiovascular dis-
ease will be the subject of coming research efforts.
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In conclusion, the present study show that decreased
TGF-β1 signaling and concentrations may be considered
as a hallmark of vascular aging in atherosclerotic patients.
Thus, the assessment of serum levels of the TGF-β1 and
its signaling in surgical samples may become a potential
tool to measure vascular aging in the clinical arena.
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